ANTI-RHEUMATIC medication
anakinra (Kineret) will be removed
from the PBS on 01 Dec, after the
PBAC recently recommended that
all prices be lowered for bDMARDs
listed on the PBS after a review of
their cost and clinical effectiveness.
Following the recommendation
the sponsor of Kineret, Invida
Australia, failed to reach a price
lowering agreement.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jul 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jul 10
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.